Sunday, August 14, 2022
    HomeHealthBiotech's Catch-22, $100 genome, & monkeypox response

    Biotech’s Catch-22, $100 genome, & monkeypox response


    Wailing gene remedy ever reside as much as expectations? Can anybody break up the genomics monopoly? And is innovation really unhealthy for biotech?

    We cowl all that and extra this week on “The Readout LOUD,” STAT’s biotech podcast. Well being care strategist Jared Holz of Oppenheimer joins us to debate the weekend’s huge oncology convention and what it would take to alter Wall Avenue’s dire view of the drug trade. We additionally talk about a weighty FDA assembly on gene remedy, the potential of a $100 genome, and the way the increasing monkeypox outbreak is creating challenges for public well being businesses.

    For extra on what we cowl, right here’s the latest on cheap genomics; right here’s more on monkeypox; right here’s an update on biotech malaise; right here’s where you can find episodes of Color Code; right here’s where you can subscribe to the First Opinion Podcast; and right here’s our complete coverage of the Covid-19 pandemic.


    Be sure you join on Apple Podcasts, Spotify, StitcherGoogle Play, or wherever you get your podcasts.

    And when you have any suggestions for us — subjects to cowl, friends to ask, vocal tics to stop — you’ll be able to e-mail [email protected].

    Source link

    Related articles

    Stay Connected


    Latest posts